Unilife reports earnings, MedImmune deal sends shares higher on the day

Unilife (UNIS) is flat AH following the release of FQ1 results.

CEO Alan Shortall says the $3.2M of revenue the company recorded for the period marks "an inflection point." "From here, I expect the slope to be significant," Shortall adds. (PR)

The shares rallied 9.5% during the regular session after the company announced a supply agreement with MedImmune under which UNIS "will supply customized devices from its platform of ReadyToGo wearable injectors."

Although UNIS said it would "generate revenue starting in Q1," other financial terms weren't disclosed. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs